Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment

Simple item page
dc.contributor.authorPirildar S.
dc.contributor.authorGönül A.S.
dc.contributor.authorTaneli F.
dc.contributor.authorAkdeniz F.
dc.date.accessioned2024-07-22T08:24:18Z
dc.date.available2024-07-22T08:24:18Z
dc.date.issued2004
dc.description.abstractBrain-derived neurotrophic factor (BDNF) has been suggested to be involved in the etiology of schizophrenia. There is a line of evidence that disruption of neurotrophins could play a role in the etiology of schizophrenia, and antipsychotics show their effect by altering levels of neurotrophins. The aim of this study was to evaluate the effect of antipsychotics on serum BDNF levels and their relationship with the symptoms in patients with schizophrenia. Twenty-two schizophrenia patients were enrolled in the study. The control group consisted of 22 age- and sex-matched physically and mentally healthy volunteers (7 male, 15 female). Serum BDNF levels and the positive and negative syndrome scale (PANSS) scores were recorded at baseline and after 6 weeks of treatment. Serum BDNF levels were also recorded in the control group. Schizophrenia patients who failed to meet 30% improvement in PANSS score were excluded from the study. The baseline serum BDNF levels of schizophrenia patients were lower than those of controls (t=4.56; df=21; p<0.001). There was no correlation between serum BDNF levels and PANSS scores in patients with schizophrenia (p>0.05). Although PANSS (for positive symptoms p<0.001, for negative symptoms p<0.001) and general psychopathology (t=20.9; df=22; p<0.001) scores improved significantly after 6 weeks of antipsychotic treatment; there was no change in BDNF levels in patients' serum (p>0.05). Our results support the view that BDNF would be associated with schizophrenia. However, we could not conclude that treatment with antipsychotics alters serum BDNF levels in patients with schizophrenia. © 2004 Elsevier Inc. All rights reserved.
dc.identifier.DOI-ID10.1016/j.pnpbp.2004.05.008
dc.identifier.issn02785846
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19920
dc.language.isoEnglish
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAntipsychotic Agents
dc.subjectBiological Markers
dc.subjectBrain-Derived Neurotrophic Factor
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPsychiatric Status Rating Scales
dc.subjectSchizophrenia
dc.subjectatypical antipsychotic agent
dc.subjectclozapine
dc.subjectneurotrophic factor
dc.subjectolanzapine
dc.subjectrisperidone
dc.subjectadolescent
dc.subjectadult
dc.subjectage
dc.subjectarticle
dc.subjectbrain
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectdrug effect
dc.subjectevaluation
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectmental disease
dc.subjectmental health
dc.subjectpatient
dc.subjectprotein blood level
dc.subjectrecording
dc.subjectschizophrenia
dc.subjectscoring system
dc.subjectsex
dc.subjectsymptom
dc.titleLow serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment
dc.typeArticle

Files

Collections

Scopus Koleksiyonu